Showing results (11-20 of 53) with videos related to
Sort By:
Pageof 6
BMC Endocrine Disorders|May 3, 2011
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 yearsKristin Taylor, Kate Gurney, Jenny Han, et al.Diabetes, Obesity & Metabolism|January 7, 2017
Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequencesMichael Horowitz, Vanita R Aroda, Jenny Han, et al.Journal of Diabetes and Its Complications|January 3, 2019
Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 studyAthena Philis-Tsimikas, Carol H Wysham, Elise Hardy, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 5, 2018
Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 DiabetesSteven P Marso, Elise Hardy, Jenny Han, et al.Current Medical Research and Opinion|March 14, 2014
Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titrationJohn B Buse, Jenny Han, Stephan Miller, et al.Cardiovascular Diabetology|March 18, 2011
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesRobert Ratner, Jenny Han, Dawn Nicewarner, et al.Cardiovascular Diabetology|March 26, 2013
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goalsAlison R Meloni, Mary Beth DeYoung, Jenny Han, et al.Postgraduate Medicine|May 14, 2010
Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetesThomas Blevins, Jenny Han, Dawn Nicewarner, et al.Clinical Therapeutics|May 22, 2012
Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in HungaryTibor Iványi, József Fövényi, Péter Faludi, et al.Clinical Therapeutics|April 7, 2005
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)Federico Calara, Kristin Taylor, Jenny Han, et al.Pageof 6